Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 12, 2026
Inovio Pharmaceuticals, Inc. (INO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $6.0 million. Free cash flow was -$18.0 million. As of Jun 30, 2026 it held $36.7 million in cash and investments and $8.0 million in total debt.
Revenue
$0
Net income
$-6.01M
+74.4% vs year-ago quarter
Operating cash flow
$-18.05M
+13.3% vs year-ago quarter
Free cash flow
$-18.05M
+13.4% vs year-ago quarter
EPS
$-0.07
+88.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
103.40M
+94.6% vs year-ago quarter
Net cash
$28.67M
Q2 FY2026
Operating margin
-38337.0%
Q1 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Plymouth Meeting, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1055726
- Former names
- INOVIO BIOMEDICAL CORP (until May 11, 2010); GENETRONICS BIOMEDICAL CORP (until Apr 1, 2005); GENETRONICS BIOMEDICAL LTD (until Aug 3, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$18.6M | -$21.9M | -$17.5M | -$21.2M | -$23.1M |
| Net income | -$6.0M | -$19.7M | $3.8M | -$45.5M | -$23.5M |
| Diluted EPS | -$0.07 | -$0.28 | $0.06 | -$0.87 | -$0.61 |
| Operating cash flow | -$18.0M | -$21.6M | -$19.4M | -$21.6M | -$20.8M |
| Free cash flow | -$18.0M | -$21.6M | -$19.5M | -$21.6M | -$20.8M |
| Total assets | $49.4M | $49.8M | $74.3M | $69.4M | $68.2M |
| Total liabilities | $45.0M | $43.7M | $50.2M | $77.1M | $39.7M |
| Stockholders' equity | $4.4M | $6.1M | $24.1M | -$7.7M | $28.5M |
| Cash and investments | $36.7M | $37.7M | $58.5M | $50.8M | $47.5M |
| Total debt | $8.0M | $8.7M | $9.4M | $10.0M | $10.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 2, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 31, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
All 1000 Inovio Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.